Infervision vs Riverain Technologies (2026)
Both detect lung nodules on chest imaging as concurrent read tools, available alongside the radiologist's initial read rather than after it, so the split is breadth and regulatory reach against evidence you can inspect and a deployment that stays inside your institution. If you want the widest coverage and multi jurisdiction footprint, start with Infervision, which spans the widest scope in the imaging lane, but its published performance evidence is thin and it is China headquartered, which raises cross border data questions. If you want a focused lung nodule tool with an inspectable clearance record and imaging that stays on premise, start with Riverain, accepting an older and narrower product. Infervision is cleared across five regulatory regimes. Riverain was the first device cleared for concurrent reading.
- The widest scope in the imaging lane: lung CT, chest radiography, and coronary CTA detection plus surgical planning across thorax, liver, and urology and standardized tumor response assessment, far beyond Riverain's cardiothoracic focus.
- The broadest multi jurisdiction footprint in the index: cleared across the US FDA, European CE, UK UKCA, Japan PMDA, and China NMPA, with iterative US clearances including 4 mm nodule detection.
- Long running deployment at scale, more than 380 sites processing over 55,000 cases daily, including UN procured tuberculosis screening in low resource settings.
- An inspectable clearance record: performance broken out by nodule type, residual analysis across slice thickness, and a site configurable micro nodule threshold, where Infervision publishes no sensitivity, specificity, or reader study data at all.
- A distinct technical mechanism: deep learning vessel suppression that alters the image so both the algorithm and the human read better, cleared in 2016 as the first device supporting concurrent reading, with a multi reader study reporting a 29 percent reduction in missed actionable nodules.
- A deployment that keeps imaging inside the institution: it installs without new hardware and likely on premise, an advantage for buyers with data residency constraints, and it is US headquartered.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Infervision and Riverain Technologies are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Infervision | Riverain Technologies |
|---|---|---|
| Primary category | Radiology & Imaging AI | Radiology & Imaging AI |
| Founded | 2015 | 2000 |
| Headquarters | Beijing, China | Dayton, Ohio, United States |
| Website | global.infervision.com | riveraintech.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Infervision its top capability grade on AI Centrality, FDA and Regulatory Status and Setting and Specialty Coverage. Set against Riverain Technologies, Infervision grades higher on FDA and Regulatory Status and Setting and Specialty Coverage. Its thinnest published disclosure sits on Model Supply Chain Disclosure and AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
The AI Health Index awards Riverain Technologies its top capability grade on AI Centrality. Set against Infervision, Riverain Technologies grades higher on several axes, including Model and Technology Transparency, Model Supply Chain Disclosure and Clinical and Operational Evidence. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
Questions buyers ask
Should we choose Infervision or Riverain Technologies?
On the axes where the AI Health Index separates them, Infervision grades higher on FDA and Regulatory Status and Setting and Specialty Coverage, and Riverain Technologies grades higher on several axes, including Model and Technology Transparency, Model Supply Chain Disclosure and Clinical and Operational Evidence. Riverain Technologies leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Infervision and Riverain Technologies differ most?
The widest separation the AI Health Index records between Infervision and Riverain Technologies is on Setting and Specialty Coverage, where Infervision grades A and Riverain Technologies grades C. That axis sits in the Commercial group, so it should carry the most weight for a buyer whose binding constraint is contracting, scope and what the price actually covers.
Where do Infervision and Riverain Technologies grade the same?
The AI Health Index grades Infervision and Riverain Technologies the same on several axes, including AI Centrality, Autonomy and Oversight Model and AI Safety and PHI Stewardship. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Infervision and Riverain Technologies not disclosed?
At the last review, at least one of Infervision and Riverain Technologies published thin or absent detail on Model Supply Chain Disclosure and AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Both detect lung nodules on chest imaging as concurrent read tools, available alongside the radiologist's initial interpretation rather than after it, which trades faster workflow for greater exposure to automation bias, the opposite of a second read design.
Infervision is the weaker on evidence despite its scale: no peer reviewed reader study, accuracy paper, or outcome data was located for any product in its line, and scale of use is not evidence of benefit, which matters most for its 4 mm nodule claim where false positive rates rise sharply. It is China headquartered and processes US and European imaging, so cross border data transfer terms are a live procurement question its materials do not address.
Riverain is an older generation of authorization with a narrow cardiothoracic scope, and its foundational clearance predates current standards such as Predetermined Change Control Plans. Neither publishes pricing or a security attestation.